NEWS

2024.06.13
Advisor

Dr. Prema Padmanabhan (Sankara Nethralaya) Joins Our Company as an Advisor

We are honored to welcome the world-renowned ophthalmologist, Dr. Prema Padmanabhan, as an advisor to our company. Dr. Padmanabhan has been a leading figure in treating corneal diseases at Sankara Nethralaya, one of India’s premier eye hospitals, for many years. Sankara Nethralaya is one of the largest eye specialty hospitals globally, known for its cutting-edge treatments and research, attracting patients and specialists from across India and around the world.

Leveraging Dr. Padmanabhan’s extensive experience and exceptional expertise, our company aims to accelerate the development of treatments for corneal diseases. This collaboration will enable us to swiftly bring innovative therapies to market, significantly improving patients’ quality of life. With Dr. Padmanabhan’s invaluable guidance, we are poised to take our product development to new heights and achieve groundbreaking advancements in the field.

2024.05.14
Advisor

Professor Keith H. Baratz (Mayo Clinic) Joins Our Advisory Team

Professor Baratz serves as a distinguished professor of ophthalmology at the Mayo Clinic, one of the leading medical institutions in the United States. Specializing in corneal diseases, he has performed numerous ophthalmic surgeries, including corneal transplants. His groundbreaking research includes findings that the SNP in the TCF4 gene is associated with Fuchs corneal endothelial dystrophy, which accounts for approximately 40% of corneal transplantation cases in the world1. Furthermore, he discovered that a trinucleotide repeat sequence expansion in the TCF4 gene is present in about 80% of patients with the disease2, which has greatly influenced the understanding of the disease’s mechanism and the development of treatments.

 

Professor Baratz’s role as an advisor to our company is pivotal. His expertise and insights will be instrumental in the development of treatments for Fuchs’ endothelial dystrophy and products related to corneal endothelial regeneration.

 

  1. Baratz KH, Tosakulwong N, Ryu E, et al. E2-2 protein and Fuchs’s corneal dystrophy. N Engl J Med 2010;363:1016-1024.
  2. Wieben ED, Aleff RA, Tosakulwong N, et al. A common trinucleotide repeat expansion within the transcription factor 4 (TCF4, E2-2) gene predicts Fuchs corneal dystrophy. PloS one 2012;7:e49083.

This website uses cookies for the purpose of operating our services and improving the user experience. For details, please refer to our privacy policy. By clicking on the “Agree” button or continuing to use our website, you will be regarded as having agreed to our use of cookies.

Agree